

1 **Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: results of the Stepped Wedge**  
2 **Cluster-randomised FIND'EM Trial**

3 Amber Meulenbeld<sup>1,2</sup>, [a.meulenbeld@sanquin.nl](mailto:a.meulenbeld@sanquin.nl)

4 Steven Ramondt<sup>1,3</sup>, [s.ramondt@sanquin.nl](mailto:s.ramondt@sanquin.nl)

5 Maike G. Sweegers<sup>1</sup>, [m.sweegers@nki.nl](mailto:m.sweegers@nki.nl)

6 Franke A. Quee<sup>1,2</sup>, [f.quee@sanquin.nl](mailto:f.quee@sanquin.nl)

7 Femmeke J. Prinsze<sup>1</sup>, [f.prinsze@sanquin.nl](mailto:f.prinsze@sanquin.nl)

8 Emiel O. Hoogendijk<sup>4,5</sup>, [e.hoogendijk@amsterdamumc.nl](mailto:e.hoogendijk@amsterdamumc.nl)

9 Dorine W. Swinkels<sup>6,7</sup>, [dorine.swinkels@radboudumc.nl](mailto:dorine.swinkels@radboudumc.nl)

10 Katja van den Hurk<sup>1,2</sup>, [k.vandenhurk@sanquin.nl](mailto:k.vandenhurk@sanquin.nl)

11

12 1. Donor Studies, Donor Medicine Research, Sanquin Research, Amsterdam, the Netherlands;

13 2. Department of Public and Occupational Health, Amsterdam Public Health research institute,  
14 Amsterdam UMC, Amsterdam, the Netherlands;

15 3. Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, the  
16 Netherlands;

17 4. Department of Epidemiology and Data Science, Amsterdam Public Health research institute,  
18 Amsterdam UMC, Amsterdam, the Netherlands;

19 5. Department of General Practice, Amsterdam Public Health research institute, Amsterdam  
20 UMC – Location VU University medical center, Amsterdam, the Netherlands;

21 6. Department of Laboratory Medicine, Radboud University Nijmegen, Nijmegen, Gelderland,  
22 The Netherlands;

23 7. Center for Iron Disorders Sanquin, Sanquin Blood Supply Foundation, Amsterdam, Noord-  
24 Holland, The Netherlands.

25

26 Running head: FIND'EM: A stepped wedge trial of ferritin monitoring in blood donors

27 Words (max. 3000): 2972

28

29 **Corresponding author**

30 Amber Meulenbeld

31 Sanquin Research

32 Plesmanlaan 125

33 PO box 9137

34 1006 AC Amsterdam, the Netherlands

35 E-mail: a.meulenbeld@sanquin.nl

36 **Abstract**

37 **Importance** Blood donors are at increased risk for iron deficiency. Current hemoglobin (Hb)  
38 monitoring policies are inadequate and new iron management strategies are warranted.

39 **Objective** To determine the effects of ferritin-guided donation intervals for whole blood donors on  
40 Hb and ferritin levels, Hb deferral, iron deficiency (ferritin < 15 ng/mL) prevalence, donor return, and  
41 iron deficiency-related symptoms.

42 **Design** Between November 2017 and November 2019 a ferritin-guided donation interval policy was  
43 gradually implemented nationwide and evaluated through a stepped-wedge cluster-randomized  
44 controlled trial.

45 **Setting** All blood collection centers in the Netherlands.

46 **Participants** 412,888 whole blood donors were included.

47 **Interventions** Ferritin was measured in all new donors and at every 5<sup>th</sup> whole blood donation.  
48 Subsequent donation intervals were extended to six months if ferritin is  $15 \leq 30$  ng/mL and to twelve  
49 months if ferritin is <15 ng/mL (iron deficient).

50 **Main outcomes and Measures** The primary outcomes are ferritin and Hb levels, iron deficiency, Hb  
51 deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms.

52 **Results** We measured 36,099 donors, median age 43 years and 52% female, making 37,621  
53 donations during the study period. Ferritin-guided donation intervals increased log-transformed  
54 ferritin levels at all time points in the trial, up to 0.56 log-transformed ng/mL as compared to baseline  
55 (95% CI 0.49 – 0.63,  $p < 0.001$ ). Hb increased as well, up to 0.39 g/dL (95% CI 0.32 – 0.45,  $p < 0.001$ ).  
56 Decreased odds of 13% (95% CI 8 – 22,  $p < 0.001$ ) for iron deficiency and 20% (95% CI 6 – 47,  $p$   
57 <0.001) for Hb deferral were reported compared to baseline. Odds of donor return decreased over  
58 the course of the trial, as low as 56% (95% CI 48 – 66,  $p < 0.001$ ). We found no evidence for improved  
59 self-reported iron deficiency-related symptoms after implementation of the new policy.

60 **Conclusion and Relevance** Ferritin-guided donation intervals significantly increased overall Hb and  
61 ferritin levels, thereby decreasing the prevalence of iron deficiency and Hb deferrals in whole blood

62 donors. Ferritin-guided donation intervals seem beneficial for Hb levels and iron maintenance, but  
63 additional efforts are required to retain donors and to remedy self-reported iron deficiency-related  
64 symptoms.

65 **Trial Registration** This trial has been registered in the Dutch trial registry (NTR6738) on September  
66 29<sup>th</sup>, 2017 (<https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738>).

67 Key words: blood donation, donation interval, donor health, stepped wedge cluster randomized trial,  
68 ferritin

## 69 Introduction

70 Annually, more than 100 million whole blood donations are made worldwide to provide life-saving  
71 treatment for patients requiring transfusion (1). However, whole blood donors that donate  
72 repeatedly are at risk of developing iron deficiency and subsequent anemia (2). Male donors lose  
73 approximately 8% of their total iron stores with each whole blood donation, whereas menstruating  
74 women can lose up to 81% of their total iron stores (3–5). Iron stores can be monitored through  
75 measuring ferritin levels. Iron deficiency, defined as ferritin levels <15 ng/ml, is present in  
76 approximately 15.0% of female and 9.4% of male Dutch repeat donors (6).

77

78 There is no consensus on strategies for donor iron management to ensure donor health. Currently,  
79 two main strategies are being used to prevent iron deficiency in whole blood donors: extending  
80 donation intervals or providing iron supplements (7–9). Negative perceptions regarding iron  
81 supplementation, adverse effects like gastrointestinal disturbances, and poor compliance could be  
82 reasons to prefer extended donation intervals over iron supplementation (9,10). In previous studies,  
83 extended donation intervals were associated with lower risk of Hb deferrals (11,12). The randomized-  
84 controlled INTERVAL trial showed that donation intervals of 12 and 16 weeks for men and women,  
85 respectively, leads to significantly higher Hb and ferritin levels compared to intervals of 8 and 12  
86 weeks (12). Most blood establishments have implemented an Hb-based monitoring policy to protect  
87 donor health, prevent anemia and ensure a sufficient Hb content in the product, deferring blood  
88 donors with Hb levels below 13.5 g/dL (males) or 12.5 g/dL (females) (7–9,13–15). However, iron  
89 deficiency can present without low Hb, especially in repeat donors. As Hb levels do not reflect iron  
90 stores, the current standard of Hb monitoring is insufficient to ensure the maintenance of proper  
91 iron reserves and donor health. The World Health Organization (WHO) advises additional monitoring  
92 of ferritin in donors to detect iron deficiency and monitor donor health (16).

93

94 In 2017, a new nationwide policy for iron monitoring of whole blood donors was implemented by  
95 Sanquin Blood Bank in The Netherlands. In addition to the existing capillary Hb measurement at the  
96 pre-donation screening, a ferritin measurement is conducted in venous samples at the first donation  
97 of new donors and after every fifth whole blood donation of repeat donors. If ferritin levels are  
98 between 15 and 30 ng/mL or below 15 ng/mL, the subsequent donation interval is extended to six or  
99 twelve months, respectively. A stepped-wedge approach, with random cross-over of blood collection  
100 centers from the existing to the new policy, was used to evaluate the effects of this ferritin-guided  
101 donation interval policy for whole blood donors on (1) Hb and ferritin levels, (2) iron deficiency, (3)  
102 Hb deferral, (4) donor return rates, and (5) self-reported iron deficiency-related symptoms.

103

## 104 **Methods**

### 105 *Design*

106 Ferritin measurement IN Donors—Effectiveness of iron Monitoring (FIND’EM) is a stepped wedge  
107 cluster-randomized trial, described in detail by Sweegers et al. (17). During the study period, between  
108 November 2017 and November 2020, 1,643,700 donations were made by 412,888 donors. we  
109 measured ferritin levels before, during, and at full implementation (twice) in all donations made by  
110 new and repeat donors visiting a blood collection center during one pre-selected week. Stored blood  
111 samples from donors who gave permission to “use remainders of [their] donation available for  
112 medical scientific research in general” were used for ferritin measurements. Furthermore, donors  
113 were asked to read the study information and sign the informed consent forms if they were  
114 interested in completing additional questionnaires. The trial was powered on the ferritin level  
115 outcome (17). The policy and implementation strategy was reviewed and approved by Sanquin’s  
116 Medical and Ethical Advisory boards. The trial was approved by Sanquin’s Board of Directors.

117

### 118 *Randomization*

119 Before randomization, the 50 fixed blood collection centers in the Netherlands were divided over 29  
120 blood collection clusters. These clusters were randomly assigned to four randomization groups. The  
121 stepped wedge design involved random and sequential crossover of all 29 clusters, by group, from  
122 the current policy to the policy including ferritin-guided donation intervals, until all clusters had  
123 implemented the new policy. The allocation was not concealed and the planned timing of each  
124 cluster's crossover was revealed before the study. Stepwise implementation of the new policy  
125 resulted in a gradually decreasing control group and a simultaneously increasing intervention group  
126 (17). Implementation started in November 2017 and was completed in November 2019.

127

#### 128 *Procedures*

129 As part of routine procedures, donors undergo a pre-donation screening to check their eligibility to  
130 donate by measuring Hb levels and blood pressure and assessment of recent travel, sexual and  
131 medical history. In accordance with European legislation, Hb cut-offs for donor eligibility of > 13.5  
132 g/dL for males and > 12.5 g/dL for females are used in The Netherlands (18). Donors with low Hb  
133 (measured prior to donating in capillary blood with HemoCue 201, Angelholm, Sweden) are deferred  
134 from donating for 3 months. If eligible, males can donate every 56 days up to five times a year,  
135 females every 122 days up to three times a year.

136

137 The intervention entails extended donation intervals based on ferritin measurements. The cut-offs  
138 for extended intervals were based on definitions for iron deficiency (<15 ng/mL, 12 months deferral)  
139 and reduced iron levels ( $\leq$  30 ng/mL, 6 months deferral) by Alvarez-Ossorio et al. (9). The six month  
140 interval is based on the results from Schotten et al., suggesting donation intervals of at least 180 days  
141 are required to fully replete the iron lost by donating (8). A twelve month interval is indicated for iron  
142 deficient donors in order to replete to higher levels than pre-donation. In whole blood donors,  
143 ferritin is measured at the health check before the first donation and at the pre-donation screening

144 before each fifth whole blood donation. If ferritin levels are  $> 30$  ng/mL, donors are eligible to donate  
145 at regular donation intervals. If ferritin levels are  $\leq 30$  ng/mL but  $\geq 15$  ng/mL, repeat donors are  
146 deferred for six months; new donors with ferritin levels of 15-30 ng/mL at the health check are  
147 allowed to donate, but ferritin is measured again at this first donation. After the first donation, new  
148 donor policy follows that of repeat donors. If ferritin levels are  $< 15$  ng/mL, new and repeat donors  
149 are deferred from donating for twelve months. Ferritin levels are measured again in the donation  
150 after an extended interval. Based on medical history and iron deficiency-related complaints, donor  
151 physicians could advise both new and repeat donors to visit their general practitioner and/or donate  
152 at a lower frequency (17).

153

#### 154 *Outcome assessment*

155 Before the start of the trial, we defined three measurement points: 1) a week before implementation  
156 (i.e., baseline), 2) a week at mid-implementation (when 55% of blood collection centers had  
157 implemented the policy) and 3) a week after complete implementation of ferritin-guided donation  
158 intervals. Hb and ferritin levels, Hb deferral, iron deficiency, donor return are primary outcomes, iron  
159 deficiency-related symptoms are secondary outcomes. For all donors that visited a blood collection  
160 center during the measurement weeks and gave consent for their information and left-over material  
161 to be used for research purposes, we extracted pseudonymized age, sex, Hb levels and deferrals from  
162 the donor database (eProgesa software application; MAK-SYSTEM, Paris, France). We defined donor  
163 return as a donation attempt within six months after being eligible to donate again, thereby taking  
164 into account minimum donation intervals and any deferrals if applicable. We measured ferritin levels  
165 on the Architect i2000sr (Abbott Diagnostics) in plasma samples collected at donation in K3EDTA  
166 tubes (VACUETTE®, Greiner Bio-One, Kremsmünster, Austria) and stored at  $-30^{\circ}\text{C}$ .

167

168 New and repeat donors who visited fixed blood collection centers during the measurement period at  
169 mid-implementation and after full implementation who signed an informed consent form were asked  
170 to complete questionnaires. These questionnaires assess physical and mental wellbeing (SF-36),  
171 fatigue (Checklist Individual Strength), donation-related symptoms, restless legs syndrome (RLS) and  
172 pica, cognitive functioning (Cognitive Failure Questionnaire), and warm glow (12,17,19–22).  
173 Questionnaires could be accessed through a hyperlink or a QR-code and were completed using  
174 Qualtrics XM® software (Provo, UT, USA) during or shortly after the donation. Donors who were  
175 unable to complete the online questionnaires were provided with paper versions or sent the  
176 questionnaires through (e-)mail (17).

177

#### 178 *Data analyses*

179 Descriptive statistics are provided for the donor population at baseline. We used ordinary least  
180 squares regression in case of continuous outcomes and logistic regression for binary outcomes. We  
181 conducted robust regression analyses for questionnaire data with continuous outcomes due to  
182 outliers. Measurements after implementation were grouped in periods of 6 months and compared to  
183 the control condition, which was defined as no implementation of the new policy or implementation  
184 less than 6 months ago. Analyses were adjusted for age, weight and height. Stratified analyses were  
185 performed to investigate differences in the effectiveness of ferritin-guided donation intervals  
186 between male and female donors. A two-sided p-value of  $<0.05$  is considered statistically significant.

187

#### 188 *Deviations from protocol*

189 Due to the impact of the new policy on the blood supply after implementation in the first group,  
190 further implementation executed in smaller steps (17). Additional ferritin measurements were done  
191 on samples from all donations one year after the last measurement round (between November 23<sup>rd</sup>  
192 and 27<sup>th</sup> 2020). The fourth measurement timepoint was added to enable evaluation long-term  
193 results, as effects of the policy were expected and observed to only show after a while, due to the

194 long deferrals and the relatively small number of donors measured at once. We furthermore  
195 deviated from the protocol by using ordinary least squares regression instead of linear mixed models  
196 after assessment of the intraclass correlation coefficient, that ranged from 0.000 to 0.007. Lastly, we  
197 conducted an additional logistic regression analysis for donor return for which we separated donors  
198 with ferritin  $\leq 30$  and  $> 30$  ng/mL.

199

## 200 **Results**

201 A total of 412,888 whole blood donors made 1,634,700 donations during the study and  
202 implementation period. We performed additional measurements in samples of 37,621 donations by  
203 36,099 donors (Figure 1). Table 1 shows the baseline characteristics of participating donors by sex  
204 and randomization group. Overall, across the randomization groups, donors were well balanced with  
205 respect to characteristics and comparable with the general donor population (Table 1)(23). Baseline  
206 characteristics of the 7,573 participants in the questionnaire are provided in Table S1.

207

208 Figure 2 shows that, in all groups, the prevalence of both iron deficiency and Hb deferral decreased  
209 during trial. Ferritin-guided donation intervals are associated with significantly higher ferritin and Hb  
210 levels and less iron deficiency and Hb deferrals (Table 2). Compared to pre-implementation, the  
211 intervention was associated with up to 0.56 log-transformed ng/mL higher ferritin and 0.39 g/dL  
212 higher Hb at 36 months after implementation in males (Table 2). In both premenopausal and  
213 postmenopausal females, we also observe positive associations, albeit smaller, with an increasing  
214 trend over time since implementation. Moreover, at 36 months after implementation, the odds ratio  
215 of 0.19 indicates that males are 81% less likely to be iron deficient than at pre-implementation (Table  
216 2). In postmenopausal females, odds ratios also decrease over the course of the trial, with iron  
217 deficiency being 87% less likely at 36 months after implementation as compared to pre-  
218 implementation (Table 2). Hb deferral in males was up to 73% less likely as time since  
219 implementation increased, compared to pre-implementation. Similarly, in premenopausal females,

220 Hb deferral is up to 35% less likely at full implementation than at pre-implementation (Table 2). In  
221 postmenopausal females, Hb deferral is up to 49% less likely than at pre-implementation.

222

223 The odds for donors to return within six months of the first allowed donation date are lower at each  
224 timepoint after implementation compared to pre-implementation (Table 2). At 36 months after  
225 implementation, males were 43% less likely to return for donation (Table 2). For premenopausal  
226 females, we do not observe a clear decrease in odds over the course of the trial, while for  
227 postmenopausal females, the odds to return for a donation do decrease but are not statistically  
228 significant at all timepoints (Table 2). Table S2 shows that after implementation odds for return are  
229 mostly lower in donors with ferritin levels  $\leq 30$  compared to donors with ferritin  $> 30$  ng/mL.  
230 However, there is no significant difference between the two groups: confidence intervals overlap at  
231 most timepoints.

232

233 There was no evidence of improvement of self-reported iron deficiency-related outcomes after  
234 implementation of the new policy. There were no consistent significant patterns for pica, fatigue,  
235 cognitive functioning, the SF-36, and warm glow (Table 3). However, the reporting of RLS increased.  
236 Compared to pre-implementation, premenopausal females, postmenopausal females, and males  
237 were 185%, 111%, and 106% more likely to report RLS at 24 months after implementation than at  
238 pre-implementation.

239

## 240 **Discussion**

241 Our stepped-wedge cluster-randomized trial among Dutch whole blood donors shows that ferritin  
242 and Hb levels are significantly higher and iron deficiency and Hb deferral prevalence significantly  
243 lower after the implementation of ferritin-guided donation intervals in comparison to the prior  
244 standard of Hb monitoring only. Conversely, we found that the odds for donor return within six  
245 months decreased substantially after implementation of this policy. The new policy did not affect

246 most self-reported iron deficiency related symptoms, but was associated with increased reporting of  
247 RLS.

248

249 The new policy was associated with being significantly less likely to be iron deficient and higher  
250 ferritin and Hb levels compared to pre-implementation, which aligns with findings in donor  
251 population simulations that assess the impact of ferritin testing (24). A possible explanation for the  
252 weaker effects in premenopausal females compared to other groups may be that already at pre-  
253 implementation, premenopausal females were more frequently deferred, a measure of a similar  
254 nature that is part of the pre-implementation Hb monitoring policy, and return less. This allows more  
255 recovery time from donations. Additionally, because of more stable iron stores due to the healthy  
256 donor effect, their lower donation frequency and baseline ferritin levels, the remaining pool of  
257 premenopausal donors may not show associations as strong as the other groups (25,26).

258

259 Our finding that the new policy is associated with significantly lower odds for donor return supports  
260 previous findings on the effects of deferral on donor return, but may additionally be explained by the  
261 negative effects of the COVID-19 pandemic on blood donation intentions (27–30). Return within six  
262 months for donors measured during both weeks at full implementation overlapped with lockdowns  
263 due to the COVID-19 pandemic in The Netherlands. However, the negative association of the new  
264 policy with donor return in premenopausal females was weaker compared to other groups, which  
265 may be explained by their exposure to more frequent deferral through the old Hb monitoring policy.

266

267 The increased reporting of RLS seems surprising, but may simply be a result of an increased  
268 awareness as a result of information provided to the donor upon implementation. Further  
269 investigation shows no statistically significant correlation between RLS and ferritin levels. The lack of  
270 improvement we found in self-reported iron deficiency-related symptoms aligns with previous  
271 randomized placebo-controlled trials investigating the effects of iron repletion, albeit through iron

272 supplementation, on self-reported donor health (31–33). In addition, the steady reduction in iron  
273 deficiency and Hb deferral may have delayed positive effects on self-reported iron deficiency-related  
274 symptoms, which would require longer follow-up in future studies.

275

276 Our findings raise important policy and practical considerations. First, our results suggest that a  
277 ferritin-guided donation interval policy effectively reduces iron deficiency and Hb deferral in whole  
278 blood donors. This supports the WHO’s advice to conduct additional monitoring of ferritin to detect  
279 iron deficiency and monitor donor health (16). Furthermore, it provides policymakers with a  
280 monitoring option that requires no effort from blood donors, may be more effective in protecting  
281 donor’s iron status than standard Hb monitoring practices and does not impose a risk of side effects  
282 as related to iron supplementation (10). However, the decreasing odds of donor return stresses the  
283 need for intensified efforts to retain donors after implementation of this policy, specifically in donors  
284 whose intervals were extended. We encourage intensified donor recruitment with the  
285 implementation of prolonged donation intervals to ensure the continuity of the blood supply,  
286 because of the effects on donor return and decreased donor availability due to the prolonged  
287 donation intervals (34). Iron supplementation can be considered as an alternative or additional  
288 strategy, as it may involve less deferral and extended donation intervals and thus benefit donor  
289 availability (24,35). Nevertheless, there are also long-term benefits to a ferritin-guided donation  
290 interval policy: initial evaluations and the results presented here suggests that donors subjected to  
291 this policy might be deferred less often on site and are less likely to discontinue their donor career,  
292 resulting in a more stable donor pool (34).

293

294 To our knowledge, this is the first randomized study that goes beyond the limitations of Hb  
295 monitoring by evaluating the effectiveness of ferritin-guided donation intervals in improving Hb and  
296 ferritin levels, donor return rates and decreasing iron deficiency, Hb deferrals, and iron deficiency-  
297 related symptoms. One of the major strengths of this trial is the stepped wedge cluster-randomized

298 approach as it allows simultaneous implementation and evaluation of a new policy. However, there  
299 are also limitations to this study. The nature of the intervention poses a risk of overestimating the  
300 positive effect of ferritin-guided donation intervals. Donors with low ferritin, whose donation  
301 intervals are extended, may not return frequently, potentially resulting in selection bias. However,  
302 the risk of overestimation is to some extent minimized as the duration of the trial exceeds the length  
303 of extended donation intervals. There may even be underestimation of the effect on iron deficiency,  
304 as cut-offs for iron deficiency used in this study are lower than suggested in literature (36,37).  
305 Furthermore, even though donor loss may be detrimental for the blood supply, extended intervals  
306 could be beneficial for the health of donors struggling to maintain sufficient iron levels. There may  
307 also be more delayed effects of this trial, because ferritin levels are measured once every five  
308 donations, which delays individual donors' actual encounter with the policy.

309

310 The FIND'EM study provides substantial evidence that ferritin-guided donation intervals increase Hb  
311 and ferritin levels and thereby effectively prevent iron deficiency and Hb deferral. Further efforts are  
312 needed to counteract the negative effects on donor return and to investigate long-term effects on  
313 donor health outcomes. Our results may help blood services worldwide to improve their donor iron  
314 management policies in order to protect donors from developing iron deficiency.

315

## 316 **Declarations**

317 *Ethics approval and consent to participate*

318 Sanquin's Ethical Advisory Board has reviewed and approved the FIND'EM protocol. Only data from  
319 donors who gave consent for their information and left-over material to be used for research  
320 purposes at the health check were included in the study. Donors who completed questionnaires  
321 provided informed consent for their questionnaire data to be matched with data from the donor  
322 database.

323

324 *Competing interests*

325 The authors declare that they have no competing interests.

326

327 *Funding*

328 The current project is supported by the ‘Product and Process Development Cellular Products Grant’

329 (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin,

330 Amsterdam, The Netherlands.

331

332 *Authors’ contributions*

333 KvdH designed the study. KvdH, MS, FP and FQ set up and coordinated data collection. AM, and SR

334 wrote the analysis plan and drafted the manuscript. AM, SR and FP conducted the analyses with

335 support from EH. The manuscript was critically reviewed and approved by all co-authors.

336

337 *Acknowledgements*

338 We would like to acknowledge all blood bank staff for their commitment to the implementation of

339 the policy and their efforts in collecting data for our study. We are thankful to all donors for their

340 contribution to the study.

## References

1. WHO. Blood safety and availability [Internet]. Beschikbaar op: <https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability>
2. Prinsze FJ, de Groot R, Timmer TC, Zalpuri S, van den Hurk K. Donation-induced iron depletion is significantly associated with low hemoglobin at subsequent donations. *Transfusion*. 2021;61(12):3344–52.
3. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. *Transfus Med*. 2008;18(1):13–27.
4. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. *Transfusion*. 2006;46(10):1667–81.
5. Brittenham GM. Iron balance in the red blood cell donor. *Dev Biol (Basel)*. 2005;120:77–82.
6. Vinkenoog M, van den Hurk K, van Kraaij M, van Leeuwen M, Janssen MP. First results of a ferritin-based blood donor deferral policy in the Netherlands. *Transfusion*. 60(8):1785–92.
7. Boulton F. Managing donors and iron deficiency. *Vox Sang*. 2004;87 Suppl 2:22–4.
8. Schotten N, Pasker-de Jong PC, Moretti D, Zimmermann MB, Geurts-Moespot AJ, Swinkels DW, e.a. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. *Blood*. 2016;128(17):2185–8.
9. Alvarez-Ossorio, Kirchner, Klüter, Schlenke. Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. *Transfusion Medicine*. 1 juni 2000;10(2):107–12.
10. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. *Cochrane Database Syst Rev*. 2014;(7):CD009532.
11. Baart AM, van den Hurk K, de Kort WL. Minimum donation intervals should be reconsidered to decrease low hemoglobin deferral in whole blood donors: an observational study. *Transfusion*. 2015;55(11):2641–4.
12. Di Angelantonio E, Thompson SG, Kaptoge S, Moore C, Walker M, Armitage J, e.a. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet*. 2017;390(10110):2360–71.
13. Spencer B. Blood donor iron status: are we bleeding them dry? *Curr Opin Hematol*. 2013;20(6):533–9.
14. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. *Jama*. 1981;245(20):2038–43.
15. Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spencer BR, e.a. Effect of iron supplementation on iron stores and total body iron after whole blood donation. *Transfusion*. 2016;56(8):2005–12.
16. WHO. Guidelines on Assessing Donor Suitability for Blood Donation. In: *Blood Donor Selection* [Internet]. Geneva; 2012. Beschikbaar op: <https://www.ncbi.nlm.nih.gov/pubmed/23700651>
17. Sweegers MG, Zalpuri S, Quee FA, Huis in 't Veld EMJ, Prinsze FJ, Hoogendijk EO, e.a. Ferritin measurement IN Donors—Effectiveness of iron Monitoring to diminish iron deficiency and low haemoglobin in whole blood donors (FIND'EM): study protocol for a stepped wedge cluster randomised trial. *Trials*. 2020;21(1):823.

18. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Guide to the preparation, use and quality assurance of blood components. European Directorate for the Quality of Medicines and HealthCare; 2017.
19. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473–83.
20. Vercoulen JHMM; SCMA; FJFM; GJMD; van der MJWM; BG. de Checklist Individual Strength (CIS). *Gedragstherapie*. 1999;32:131–6.
21. Van den Hurk K, Peffer K, Habets K, Atsma F, Pasker-de Jong PCM, Van Noord PAH, e.a. Blood donors' physical characteristics are associated with pre- and post-donation symptoms - Donor InSight. *Blood Transfus*. 2017;15(5):405–12.
22. Ferguson E, Atsma F, de Kort W, Veldhuizen I. Exploring the pattern of blood donor beliefs in first-time, novice, and experienced donors: differentiating reluctant altruism, pure altruism, impure altruism, and warm glow. *Transfusion*. 2012;52(2):343–55.
23. Timmer TC, de Groot R, Habets K, Merz EM, Prinsze FJ, Atsma F, e.a. Donor InSight: characteristics and representativeness of a Dutch cohort study on blood and plasma donors. *Vox Sang*. 2019;114(2):117–28.
24. Richard P, Fillet A, Malard L, Leclerc C, Chanut C, Woimant G, e.a. Impact of donor ferritin testing on iron deficiency prevention and blood availability in France: A cohort simulation study. *Vox Sanguinis*. januari 2023;118(1):24–32.
25. Moazzen S, sweegers M, Hogema B, Hoekstra T, van den Hurk K. Ferritin trajectories over repeated whole blood donations: results from the FIND+ study. medRxiv. 2021;2021.12.13.21267744.
26. Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. *Transfusion*. 2011;51(8):1820–8.
27. Spekman MLC, Tilburg TG, Merz E. Do deferred donors continue their donations? A large-scale register study on whole blood donor return in the Netherlands. *Transfusion*. december 2019;59(12):3657–65.
28. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. *Transfusion*. 2007;47(8):1514–23.
29. Custer B, Schlumpf KS, Wright D, Simon TL, Wilkinson S, Ness PM, e.a. Donor return after temporary deferral. *Transfusion*. 2011;51(6):1188–96.
30. Veseli B, Sandner S, Studte S, Clement M. The impact of COVID-19 on blood donations. Dickert S, redacteur. *PLoS ONE*. 24 maart 2022;17(3):e0265171.
31. Hod EA, Brittenham GM, Bitan ZC, Feit Y, Gaelen JI, La Carpia F, e.a. A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being. *Blood*. 22 december 2022;140(25):2730–9.
32. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, e.a. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. *BMC Med*. 2012;10:8.
33. Keller P, von Känel R, Hincapié CA, da Costa BR, Jüni P, Erlanger TE, e.a. The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. *Sci Rep*. 26 augustus 2020;10(1):14219.
34. Spekman MLC, Ramondt S, Sweegers MG. Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy. *Transfusion*. april 2021;61(4):1112–21.

35. Karregat J, Sweegers MG, Quee FA, Weekamp HH, Swinkels DW, Novotny VMJ, e.a. Ferritin-guided iron supplementation in whole blood donors: optimal dosage, donor response, return and efficacy (FORTE)-a randomised controlled trial protocol. *BMJ Open*. 2022;12(3):e056316–e056316.
36. Galetti V, Stoffel NU, Sieber C, Zeder C, Moretti D, Zimmermann MB. Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorption. *EClinicalMedicine*. september 2021;39:101052.
37. Tarancon-Diez L, Genebat M, Roman-Enry M, Vázquez-Alejo E, Espinar-Buitrago M de la S, Leal M, e.a. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency. *Nutrients*. 10 november 2022;14(22):4739.

**Table 1.** Donor characteristics at baseline

	Group 1 <sup>1</sup>	Group 2	Group 3	Group 4	Overall
Pre-menopausal, female donors	N = 688	N = 590	N = 634	N = 465	N = 2,377
New donors, N (%)	167 (24.3)	109 (18.5)	131 (20.7)	86 (18.5)	493 (20.7)
Age (years), median [IQR]	25.0 [21.0, 31.0]	26.0 [21.0-34.0]	26.0 [22.0-33.8]	25.0 [21.0-31.0]	25.0 [21.0-33.0]
Height (cm), mean (SD)	171 (6.4)	171 (6.9)	171 (6.3)	171 (6.4)	171 (6.5)
Weight (kg), mean (SD)	71.0 (12.2)	69.0 (12.4)	71.4 (11.9)	70.8 (12.1)	71.1 (12.2)
Hemoglobin, median [IQR], g/dL	13.4 [12.7-12.4]	12.4 [12.9-12.1]	13.5 [12.9-14.0]	13.4 [12.9-14.0]	13.4 [12.9-14.0]
Low hemoglobin deferral (<12.5 g/dL), N (%)	64 (9.3)	34 (5.8)	46 (7.3)	43 (9.2)	187 (7.9)
Ferritin, median [IQR], ng/mL	26.2 [13.3-46.2]**	24.7 4 [12.1-46.7]**	24.7 [12.7-45.5]**	23.7 [10.3-40.3]**	25.1 [12.3-45.4]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	161 (23.4)**	159 (26.9)**	173 (27.3)**	130 (28.0)**	623 (26.2)**
Total number of whole blood donations, median [IQR]	2.0 [1.0-7.0]	3.0 [1.0-9.0]	4.0 [1.0-10.0]	3.0 [1.0-9.0]	3.0 [1.0-9.0]
Number of whole blood donations in the past 2 years, median [IQR]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	3.0 [1.0-4.0]	2.0 [1.0-4.0]
Donor return within 6 months of first allowed date, N (%)	478 (66.5)	383 (64.9)	436 (68.8)	323 (69.5)	1,620 (68.2)
Post-menopausal, female donors	N = 388	N = 379	N = 387	N = 308	N = 1,462
New donors, N (%)	11 (2.8)	7 (1.8)	13 (3.4)	2 (0.6)	33 (2.3)
Age (years), median [IQR]	55.0 [49.0-60.0]	55.0 [50.0-61.0]	56.0 [49.0-60.0]	55.0 [49.8-62.0]	55.0 [50.0-61.0]
Height (cm), mean (SD)	170 (5.9)	169 (6.1)	170 (6.2)	170 (5.9)	170 (6.0)
Weight (kg), mean (SD)	74.5 (11.3)	73.4 (12.3)	73.9 (12.4)	73.3 (11.6)	73.8 (11.9)
Hemoglobin, median [IQR], g/dL	12.9 [13.1-14.5]	13.5 [13.1-14.5]	13.7 [13.1-14.3]	13.5 [13.1-14.3]	13.7 [13.1-14.3]
Low hemoglobin deferral (<12.5 g/dL), N (%)	19 (4.9)	19 (5.0)	21 (5.4)	11 (3.6)	70 (4.8)
Ferritin, median [IQR], ng/mL	27.4 [13.5-44.0]***	28.3 [14.0-45.8]**	25.7 [13.2-45.0]**	26.7 [15.0-43.6]**	27.4 [13.7-45.0]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	85 (21.9)***	87 (23.0)**	95 (24.5)**	64 (20.8)**	331 (22.6)**
Total number of whole blood donations, median [IQR]	29.0 [11.0-50.0]	26.0 [12.0-42.0]	29.0 [12.0-46.0]	29.0 [12.0-47.0]	28.0 [12.0-46.0]
Number of whole blood donations in the past 2 years, median [IQR]	5.0 [3.0-5.0]	4.0 [3.0-5.0]	5.0 [3.0-6.0]	5.0 [3.0-5.0]	5.0 [3.0-6.0]
Donor return within 6 months of first allowed date, N (%)	297 (76.5)	292 (77.0)	310 (80.1)	237 (76.9)	1,136 (77.7)
Male donors	N = 1075	N = 1061	N = 1007	N = 870	N = 4,013
New donors, N (%)	58 (5.4)	63 (5.9)	46 (4.6)	47 (5.4)	214 (5.3)
Age (years), median [IQR]	48.0 [32.0-58.5]	51.0 [35.0-60.0]	49.0 [32.5-58.0]	49.0 [31.0-59.0]	49.0 [32.0-59.0]
Height (cm), mean (SD)	184 (7.1)	183 (7.2)	183 (6.9)	183 (7.5)	183 (7.2)
Weight (kg), mean (SD)	86.5 (12.1)	85.8 (12.2)	85.4 (12.0)	85.4 (11.9)	85.8 (12.1)
Hemoglobin, median [IQR], g/dL	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.5]	14.8 [14.2-15.6]
Low hemoglobin deferral (<13.5 g/dL), N (%)	42 (3.9)	27 (2.5)	34 (3.4)	27 (3.1)	130 (3.2)
Ferritin, median [IQR], ng/mL	25.3 [12.3-54.9]**	25.9 [13.2-55.3]**	24.8 [12.4-50.0]**	24.5 [11.6-54.8]**	25.2 [12.4-53.2]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	280 (26.0)**	273 (25.7)**	272 (27.0)**	243 (27.9)**	1,068 (26.6)**
Total number of whole blood donations, median [IQR]	30.0 [7.0-68.0]	39.0 [8.0-71.0]	32.0 [8.0-64.0]	31.5 [7.0-70.0]	32.0 [7.0-68.0]
Number of whole blood donations in the past 2 years, median [IQR]	6.0 [4.0-9.0]	6.0 [4.0-9.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]

[IQR]

Donor return within 6 months of first allowed date, N (%)	924 (86.0)	905 (85.3)	870 (86.4)	738 (84.8)	3,437 (85.6)
---	------------	------------	------------	------------	--------------

<sup>†</sup>Randomly assigned clusters of donation centres (Group 1-3: 8 clusters, group 4: 5 clusters)

Missing: \* < 10%, \*\* 10-20%, \*\*\* > 20%

**Table 2.** Associations of implementation of ferritin-guided donation intervals with primary study outcomes.

Outcome	Group		Time since implementation					
			6-11 months <sup>1</sup>	12-17 months	18-23 months	24-29 months	30-35 months	36+ months
Ferritin (ng/mL, log-transformed)	PRE <sup>2</sup>	Coef (95% CI)	0.04 (-0.03 – 0.12)	<b>0.12 (0.07 – 0.18)</b>	<b>0.15 (0.07 – 0.22)</b>	<b>0.20 (0.13 – 0.27)</b>	<b>0.23 (0.12 – 0.34)</b>	<b>0.34 (0.25 – 0.44)</b>
	POST <sup>3</sup>		<b>0.13 (0.04 – 0.22)</b>	<b>0.22 (0.15 – 0.28)</b>	<b>0.28 (0.19 – 0.37)</b>	<b>0.34 (0.26 – 0.42)</b>	<b>0.40 (0.27 – 0.53)</b>	<b>0.55 (0.45 – 0.65)</b>
	Males		<b>0.22 (0.16 – 0.28)</b>	<b>0.41 (0.36 – 0.45)</b>	<b>0.46 (0.40 – 0.52)</b>	<b>0.53 (0.48 – 0.59)</b>	<b>0.54 (0.45 – 0.62)</b>	<b>0.56 (0.49 – 0.63)</b>
Iron deficiency <sup>4</sup>	PRE	OR (95% CI)	1.07 (0.90 – 1.26)	<b>0.78 (0.68 – 0.89)</b>	<b>0.71 (0.59 – 0.85)</b>	<b>0.66 (0.56 – 0.79)</b>	<b>0.61 (0.46 – 0.80)</b>	<b>0.39 (0.30 – 0.51)</b>
	POST		<b>0.77 (0.59 – 0.98)</b>	<b>0.56 (0.46 – 0.68)</b>	<b>0.40 (0.29 – 0.55)</b>	<b>0.38 (0.28 – 0.50)</b>	<b>0.35 (0.21 – 0.55)</b>	<b>0.13 (0.08 – 0.22)</b>
	Males		<b>0.51 (0.43 – 0.60)</b>	<b>0.28 (0.24 – 0.32)</b>	<b>0.21 (0.17 – 0.27)</b>	<b>0.15 (0.12 – 0.19)</b>	<b>0.15 (0.10 – 0.21)</b>	<b>0.19 (0.15 – 0.25)</b>
Hemoglobin (g/dL)	PRE	Coef (95% CI)	0.03 (-0.03 – 0.10)	<b>0.06 (0.02 – 0.11)</b>	<b>0.16 (0.10 – 0.23)</b>	<b>0.18 (0.11 – 0.23)</b>	-0.02 (-0.10 – 0.06)	<b>0.18 (0.10 – 0.24)</b>
	POST		0.08 (-0.02 – 0.18)	0.05 (-0.02 – 0.13)	<b>0.21 (0.11 – 0.29)</b>	<b>0.19 (0.11 – 0.27)</b>	0.00 (-0.13 – 0.13)	<b>0.15 (0.05 – 0.24)</b>
	Males		<b>0.15 (0.08 – 0.21)</b>	<b>0.24 (0.19 – 0.29)</b>	<b>0.31 (0.24 – 0.37)</b>	<b>0.35 (0.29 – 0.40)</b>	<b>0.29 (0.19 – 0.37)</b>	<b>0.39 (0.32 – 0.45)</b>
Hemoglobin deferral <sup>5</sup>	PRE	OR (95% CI)	0.81 (0.60 – 1.07)	0.84 (0.69 – 1.03)	<b>0.53 (0.38 – 0.73)</b>	<b>0.63 (0.47 – 0.83)</b>	<b>0.58 (0.37 – 0.86)</b>	<b>0.65 (0.46 – 0.90)</b>
	POST		0.78 (0.45 – 1.25)	0.40 (0.51 – 1.05)	0.66 (0.36 – 1.11)	<b>0.51 (0.29 – 0.85)</b>	1.03 (0.52 – 1.86)	<b>0.53 (0.28 – 0.93)</b>
	Males		0.80 (0.54 – 1.14)	<b>0.49 (0.35 – 0.67)</b>	<b>0.36 (0.20 – 0.59)</b>	<b>0.35 (0.21 – 0.54)</b>	<b>0.20 (0.06 – 0.47)</b>	<b>0.27 (0.14 – 0.49)</b>
Donor return <sup>6</sup>	PRE	OR (95% CI)	<b>0.75 (0.65 – 0.87)</b>	<b>0.86 (0.77 – 0.96)</b>	<b>0.80 (0.69 – 0.92)</b>	<b>0.74 (0.65 – 0.85)</b>	<b>0.81 (0.67 – 0.98)</b>	0.90 (0.77 – 1.06)
	POST		0.82 (0.65 – 1.02)	<b>0.84 (0.72 – 0.99)</b>	<b>0.66 (0.53 – 0.82)</b>	<b>0.68 (0.56 – 0.83)</b>	0.76 (0.56 – 1.03)	0.80 (0.64 – 1.01)
	Males		<b>0.80 (0.65 – 0.95)</b>	0.90 (0.80 – 1.03)	<b>0.66 (0.56 – 0.77)</b>	<b>0.66 (0.57 – 0.76)</b>	<b>0.68 (0.55 – 0.84)</b>	<b>0.56 (0.48 – 0.66)</b>

Bold text indicates significance at  $p < 0.05$ ; all analyses are scaled and adjusted for age, height, and weight

<sup>1</sup> Reference group: no implementation or 0-5 months since implementation

<sup>2</sup> PRE: Premenopausal females (age  $\leq 48$ )

<sup>3</sup> POST: Postmenopausal females (age  $> 48$ )

<sup>4</sup> Ferritin  $< 15$  ng/mL

<sup>5</sup> For males  $\geq 13.5$  g/dL, for females  $\geq 12.5$  g/dL

<sup>6</sup> Within six months of the first allowed date for the next donation

**Table 3.** Associations of implementation of ferritin guided donation intervals with secondary study outcomes.

Outcome	Group		Time since implementation			
			6-11 months <sup>1</sup>	12-17 months	18-23 months	24+ months
Restless legs syndrome	PRE <sup>2</sup>		<b>1.66 (1.01 – 2.70)</b>	1.12 (0.64 – 1.92)	<b>2.61 (1.54 – 4.33)</b>	<b>2.85 (1.82 – 4.48)</b>
	POST <sup>3</sup>	OR (95% CI)	<b>2.11 (1.35 – 3.27)</b>	0.55 (0.28 – 1.00)	1.06 (0.47 – 2.12)	<b>2.06 (1.22 – 3.41)</b>
	Males		1.25 (0.80 – 1.91)	0.87 (0.53 – 1.37)	<b>1.89 (1.14 – 3.03)</b>	<b>1.69 (1.13 – 2.51)</b>
Pica	PRE <sup>1</sup>		1.06 (0.29 – 2.18)	0.75 (0.29 – 1.67)	1.28 (0.50 – 2.88)	0.80 (0.29 – 1.86)
	POST <sup>2</sup>	OR (95% CI)	0.53 (0.08 – 2.05)	1.66 (0.60 – 4.38)	1.62 (0.25 – 6.31)	1.93 (0.52 – 5.87)
	Males		0.68 (0.32 – 1.31)	1.00 (0.55 – 1.72)	1.11 (0.48 – 2.25)	0.91 (0.47 – 1.65)
Fatigue <sup>4</sup>	PRE		-0.33 (-1.05 – 0.39)	0.71 (-0.03 – 1.44)	-0.86 (-1.75 – 0.04)	-0.38 (-1.17 – 0.42)
	POST	Coef (95% CI)	-0.29 (-1.09 – 0.51)	0.32 (-0.45 – 1.09)	-0.16 (-1.31 – 1.00)	-0.49 (-1.54 – 0.55)
	Males		-0.40 (-0.92 – 0.12)	-0.50 (-1.01 – 0.01)	-0.78 (-1.61 – 0.04)	-0.27 (-0.82 – 0.28)
Cognitive functioning <sup>4</sup>	PRE		0.14 (-1.35 – 1.64)	-1.46 (-2.94 – 0.03)	-0.92 (-2.62 – 0.77)	0.87 (-0.82 – 2.56)
	POST	Coef (95% CI)	0.87 (-0.77 – 2.51)	1.08 (-0.50 – 2.67)	2.59 (-0.06 – 5.23)	0.86 (-1.12 – 2.84)
	Males		0.05 (-1.04 – 1.13)	0.81 (-0.29 – 1.90)	-0.59 (-2.14 – 0.96)	-0.24 (-1.38 – 0.90)
Physical health (SF-36) <sup>5</sup>	PRE		-0.04 (-0.76 – 0.68)	0.32 (-0.39 – 1.04)	0.11 (-0.79 – 1.00)	-0.64 (-1.47 – 0.19)
	POST	Coef (95% CI)	-0.33 (-1.32 – 0.66)	<b>-1.12 (-2.14 – -0.09)</b>	-1.01 (-2.57 – 0.54)	0.78 (-0.43 – 1.98)
	Males		-0.43 (-0.98 – 0.12)	-0.47 (-1.00 – 0.07)	-0.35 (-1.07 – 0.37)	-0.12 (-0.64 – 0.40)
Mental health (SF-36) <sup>5</sup>	PRE		<b>-1.25 (-2.25 – -0.24)</b>	-0.04 (-1.01 – 0.92)	-1.29 (-2.90 – 0.32)	-0.98 (-2.14 – 0.18)
	POST	Coef (95% CI)	-0.25 (-1.20 – 0.79)	0.30 (-0.75 – 1.34)	-1.37 (-3.16 – 0.42)	0.06 (-1.13 – 1.24)
	Males		0.10 (-.56 – 0.75)	-0.46 (-1.13 – 0.22)	-0.16 (-1.10 – 0.79)	0.925 (-1.02 – 0.34)
Warm glow	PRE		0.99 (0.77 – 1.26)	<b>1.41 (1.11 – 1.80)</b>	1.03 (0.75 – 1.40)	1.06 (0.81 – 1.39)
	POST	OR (95% CI)	0.86 (0.63 – 1.18)	0.80 (0.60 – 1.07)	<b>0.43 (0.27 – 0.68)</b>	0.90 (0.62 – 1.34)
	Males		0.83 (0.67 – 1.02)	0.97 (0.79 – 1.19)	<b>0.72 (0.55 – 0.95)</b>	0.81 (0.65 – 1.00)

Bold text indicates significance at  $p < 0.05$ ; all analyses are adjusted for age, height, and weight

<sup>1</sup> Reference group: no implementation or 0-5 months since implementation


<sup>2</sup> PRE: Premenopausal females

<sup>3</sup> POST: Postmenopausal females


<sup>4</sup> Higher score indicates worse result

<sup>5</sup> Higher score indicates better result

## Males



## Premenopausal females



## Postmenopausal females

